bevacizumab,panitumumab
amgen,roche,takeda
['panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva']
paradigm phase-iii at plenary session 2022. bev or panitumumab in 1st line crc. in favor of pani.
mos 37.9, orr 82% with panitumumab (looks great!)
mos 34,3, orr 73% with bevacicumab (also good) 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine